Clinical Outcomes of Machine Perfusion and Temperature Control Systems in Heart Transplantation: Where We Stand.

Heart transplantation remains the preferred treatment for carefully selected patients with end-stage heart failure refractory to medical therapy. Advances in donor management, organ preservation, donor and recipient selection, immunosuppressive strategies, and mechanical circulatory support have significantly improved the safety and efficacy of heart transplantation. However, the persistent shortage of donor hearts and their limited preservation period continues to restrict access to this lifesaving procedure. The advent of innovative machine perfusion and temperature control systems for heart allograft preservation offers a promising avenue to address these challenges. These technologies aim to extend preservation times and enable the use of extended-criteria donors, thereby expanding the donor pool. In this review, we examine the outcomes from clinical trials, registry data, and single-center studies, utilizing the TransMedics Organ Care System Heart, Paragonix SherpaPak Cardiac Transport System, and XVIVO Heart Preservation System. As the field of heart transplantation evolves to accommodate longer ischemia times, expand organ sharing, and utilize donors previously considered marginal, the integration of these advanced technologies will be essential for optimizing post-transplant outcomes.